ARTICLE | Company News
Yabao gains Chinese rights to Lilly diabetes compound
July 7, 2014 11:41 PM UTC
Eli Lilly and Co. (NYSE:LLY) granted Yabao Pharmaceutical Group Co. Ltd. (Shanghai:600351) Chinese rights to develop and commercialize Lilly's diabetes compound LY2608204. The glucokinase ( GCK; GK) a...